Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmet Dogan

Showing results (281-290 of 371) with videos related to

Pageof 38
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Blood Advances|July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphomaDavid Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Blood|July 7, 2017
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosisMatthias Papo, Eli L Diamond, Fleur Cohen-Aubart, et al.
Haematologica|November 27, 2025
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphomaErel Joffe, Manik Uppal, Serena Zheng, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
International Journal of Molecular Epidemiology and Genetics|September 15, 2011
Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab eraLindsay M Morton, James R Cerhan, Patricia Hartge, et al.
Blood|July 7, 2026
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myelomaSham Mailankody, Sneha Mitra, Kevin Herrera, et al.
Pageof 38

Showing results (281-290 of 371) with videos related to

Sort By:
Pageof 38
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Blood Advances|July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphomaDavid Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Blood|July 7, 2017
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosisMatthias Papo, Eli L Diamond, Fleur Cohen-Aubart, et al.
Haematologica|November 27, 2025
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphomaErel Joffe, Manik Uppal, Serena Zheng, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
International Journal of Molecular Epidemiology and Genetics|September 15, 2011
Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab eraLindsay M Morton, James R Cerhan, Patricia Hartge, et al.
Blood|July 7, 2026
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myelomaSham Mailankody, Sneha Mitra, Kevin Herrera, et al.
Pageof 38